Innospec

Innospec reported Q2 revenue of $491.4 million, up 12%, and net income of $30.8 million, with all three segments delivering double-digit sales growth and adjusted EPS of $1.27. Oilfield Services led operating-income growth (+40%), while Performance Chemicals and Fuel Specialties rose 15% and 3%, respectively. Management said North Carolina repairs are ~60% complete, with full optimization expected by end-Q4 and meaningful additional capacity most likely in Q1 2027. The company ended the quarter debt-free with $250.2 million cash, repurchased shares, paid its semiannual dividend, and expects stronger operating income and cash flow in H2 2026. » More on finance.yahoo.com

At the annual general meeting about 91% of outstanding shares were represented. Shareholders re-elected Elizabeth K. Arnold and Claudia P. Poccia, approved the advisory remuneration report and confirmed the appointment of the independent auditor for 2026. In addition, Innospec reported a slightly better-than-expected Q1 with adjusted EPS of $1.05 and revenue of $453.2 million; the stock is currently trading at $80.44, and a fair value is estimated at $100.47. » More on de.investing.com

Innospec reported Q1 2026 revenue of $453.2m and adjusted earnings per share of $1.05, with both metrics slightly above analyst expectations. Operational disruptions from a severe winter storm and raw material cost inflation weighed on margins: operating profit and adjusted EBITDA fell significantly, especially in the Performance Chemicals segment. The company remains net indebted, increased its dividend by 10%, launched a new $75m share buyback program, and expects a sequential recovery in Q2 as production disruptions abate. » More on de.investing.com

Analysts estimate that Innospec will report quarterly results for the period ended March 31, 2026, on May 7, 2026: expected EPS $1.02 (−22.1% vs. year ago) and revenue of about $432.1 million (−2.0% vs. year ago). For the current fiscal year, analysts on average see EPS of $4.96 and revenue of roughly $1.87 billion, both higher than the prior year. » More on finanzen.net

Innospec’s stock fell to a 52-week low of $67.83 and is down about 30.95% year to date. InvestingPro rates the stock as significantly undervalued and sees a fair value well above the current price; the company also has a “GOOD” financial health score and a P/E ratio of 14.71. Management stock buybacks and an oversold RSI are cited as possible factors for a recovery, and Wolfe Research lists Innospec among companies vulnerable to activist investors. » More on de.investing.com